Habenbacher, M.; Moser, U.; Abaira, A.; Kiss, P.; Holzmeister, C.; Pock, J.; Walla, K.; Lang, A.; Andrianakis, A.
Investigation of Blood Count-Based Inflammatory Biomarkers as Predictors of Response to Dupilumab Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyps. Pharmaceutics 2024, 16, 1370.
https://doi.org/10.3390/pharmaceutics16111370
AMA Style
Habenbacher M, Moser U, Abaira A, Kiss P, Holzmeister C, Pock J, Walla K, Lang A, Andrianakis A.
Investigation of Blood Count-Based Inflammatory Biomarkers as Predictors of Response to Dupilumab Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyps. Pharmaceutics. 2024; 16(11):1370.
https://doi.org/10.3390/pharmaceutics16111370
Chicago/Turabian Style
Habenbacher, Michael, Ulrich Moser, Ahmed Abaira, Peter Kiss, Clemens Holzmeister, Jakob Pock, Katharina Walla, Angelika Lang, and Alexandros Andrianakis.
2024. "Investigation of Blood Count-Based Inflammatory Biomarkers as Predictors of Response to Dupilumab Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyps" Pharmaceutics 16, no. 11: 1370.
https://doi.org/10.3390/pharmaceutics16111370
APA Style
Habenbacher, M., Moser, U., Abaira, A., Kiss, P., Holzmeister, C., Pock, J., Walla, K., Lang, A., & Andrianakis, A.
(2024). Investigation of Blood Count-Based Inflammatory Biomarkers as Predictors of Response to Dupilumab Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyps. Pharmaceutics, 16(11), 1370.
https://doi.org/10.3390/pharmaceutics16111370
